Hospital
Lakewood Health System
Lakewood Health System was paid $6.06M by Medicaid between Jan 2018 and Dec 2024, across 109 billing codes. Its largest line is 41899, Unlisted procedure, dentoalveolar structures — 32% of everything it billed.
33Billing provider infoLAKEWOOD HEALTH SYSTEM
STAPLES, MN 56479
STAPLES, MN 56479
33aNPI1295726362assigned 10/28/2005
33bProvider typeCritical Access Hospital
28Total paid$6.06M
24GClaims82,699
24DCodes billed109
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Minnesota
Rank by total paid#7 of 68
Median peer was paid$798K
This provider vs. median7.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,075 | $416K | |
| 2019 | 11,152 | $944K | |
| 2020 | 11,359 | $662K | |
| 2021 | 17,466 | $1.20M | |
| 2022 | 14,796 | $1.16M | |
| 2023 | 15,509 | $1.19M | |
| 2024incomplete | 8,342 | $495K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 41899 | Unlisted procedure, dentoalveolar structures | 32% | 685 | 640 | $1.92M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 15% | 6,813 | 5,911 | $901K |
| 36415 | Collection of venous blood by venipuncture | 6.3% | 18,570 | 15,341 | $381K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.0% | 2,684 | 2,271 | $366K |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 5.9% | 805 | 674 | $357K |
| A0425 | Ground mileage, per statute mile | 5.3% | 1,373 | 1,066 | $322K |
| 80053 | Comprehensive metabolic panel | 3.4% | 4,555 | 4,169 | $203K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.9% | 813 | 711 | $178K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.9% | 2,509 | 2,412 | $173K |
| A0080 | Non-emergency transportation, per mile - vehicle provided by volunteer (individual or organization), with no vested interest | 2.5% | 4,035 | 665 | $153K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 4,544 | 4,161 | $110K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.6% | 2,183 | 1,804 | $100K |
97 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 1,819 | $91K |
| A0100 | Non-emergency taxi ride to a medical appointment | 1.3% | 4,410 | $80K |
| S0215 | Non-emergency transportation; mileage, per mile | 1.0% | 2,014 | $62K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,687 | $52K |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 232 | $46K |
| 85027 | <1% | 1,767 | $38K | |
| 64483 | <1% | 42 | $36K | |
| S0209 | Wheelchair van, mileage, per mile | <1% | 835 | $34K |
| J3490 | Unclassified drugs | <1% | 1,732 | $31K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,426 | $29K |
| T2003 | Non-emergency transportation, per trip | <1% | 1,920 | $26K |
| 86140 | <1% | 1,139 | $24K | |
| J2401 | Injection, chloroprocaine hydrochloride, per 1 mg | <1% | 734 | $21K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 66 | $17K |
| A0130 | Non-emergency transportation: wheelchair van | <1% | 875 | $17K |
| J2400 | Injection, chloroprocaine hydrochloride, per 30 ml | <1% | 396 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 457 | $14K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 154 | $14K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 174 | $13K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 227 | $13K |
| D1110 | Prophylaxis - adult | <1% | 295 | $12K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 316 | $11K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 375 | $10K |
| J2704 | Injection, propofol, 10 mg | <1% | 274 | $9K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 276 | $9K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 134 | $9K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 377 | $8K |
| D1206 | Topical application of fluoride varnish | <1% | 336 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 149 | $7K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 190 | $7K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 314 | $7K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 285 | $6K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 57 | $6K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 127 | $6K |
| D9420 | <1% | 470 | $5K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 87 | $5K |
| 87480 | <1% | 422 | $5K | |
| 87510 | <1% | 422 | $5K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 279 | $5K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 184 | $5K |
| 81001 | <1% | 754 | $5K | |
| 87660 | <1% | 422 | $5K | |
| 84439 | <1% | 170 | $4K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 102 | $4K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 13 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 194 | $3K |
| D1330 | <1% | 307 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 134 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 126 | $3K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 45 | $3K |
| 83655 | <1% | 99 | $3K | |
| 85652 | <1% | 158 | $3K | |
| 99285 | Emergency room visit (most serious) | <1% | 12 | $3K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 27 | $3K |
| 83930 | <1% | 65 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 43 | $2K |
| 82728 | <1% | 39 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 84 | $2K |
| 86850 | <1% | 84 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 43 | $2K |
| 73630 | <1% | 16 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 56 | $2K |
| 81003 | <1% | 145 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 40 | $2K |
| 85018 | <1% | 73 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 41 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 41 | $1K |
| 87088 | <1% | 40 | $1K | |
| 80061 | Lipid panel | <1% | 45 | $1K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 56 | $1K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 31 | $1K |
| 73620 | <1% | 15 | $1K | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 27 | $948.79 |
| D0120 | Dental checkup, returning patient | <1% | 41 | $793.28 |
| 87081 | <1% | 29 | $774.58 | |
| 80076 | <1% | 12 | $583.56 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 17 | $552.15 |
| 85651 | <1% | 28 | $534.36 | |
| 87186 | <1% | 17 | $476.61 | |
| 81025 | <1% | 18 | $450.00 | |
| 90682 | <1% | 24 | $438.33 | |
| 83540 | <1% | 12 | $290.30 | |
| D9920 | <1% | 389 | $108.34 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 16 | $31.68 |
| A9270 | Non-covered item or service | <1% | 46 | $12.50 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 16 | $0.37 |
| 99188 | <1% | 12 | $0.01 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 27 | $0.00 |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 0% | 12 | $0.00 |
| 90461 | 0% | 12 | $0.00 | |
| 96127 | 0% | 27 | $0.00 | |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 0% | 46 | $0.00 |
| 90834 | Psychotherapy session, about 45 minutes | 0% | 26 | $0.00 |
| 90686 | 0% | 16 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 18 | $0.00 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 76 | $0.00 |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 171 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREYCRAFT, JOSEPH (CFO)
| Provider | Location | Paid |
|---|---|---|
| Lakewood Health System | Staples, MN | $32.21M |
| Lakewood Health System | Pillager, MN | $6.05M |
| Lakewood Health System | Browerville, MN | $1.15M |
| Lakewood Health System | Motley, MN | $965K |
| Lakewood Health System | Eagle Bend, MN | $919K |
| Lakewood Health System | Staples, MN | $177K |
| Lakewood Health System | Long Prairie, MN | $104K |
| Lakewood Health System | Sartell, MN | $54K |
| Lakewood Health System | Staples, MN | $50K |
| Lakewood Health System | Staples, MN | $6K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.